Overcoming Paradigm Inertia: Publishing Incentives and Peer Review Bias as the True Rate-Limiting Steps in Reducing Animal Research

To the Editor

We read with great interest the recent perspective by Ineichen [1] regarding the urgent need to balance the scale, quality, and justification of animal research in contemporary biomedical science. The author provides a commendable roadmap for operationalizing the 3Rs framework, rightly arguing that strategic reduction is a prerequisite for efficient, responsible science rather than an impediment to progress. While we fully endorse the call to ground new studies in existing evidence and transition toward New Approach Methodologies (NAMs) such as organoids, organ-on-chip systems, and computational models, the translational community must confront the underlying cultural and institutional inertia that actively penalizes researchers who attempt to bypass animal validation [2].

Ineichen [1] notes that decisions to conduct in vivo experiments are frequently driven by academic incentives that reward publication counts and positive findings over design quality. More critically, the manuscript highlights the phenomenon of “animal methods bias,” where pressure from peer review and publishing workflows often forces the inclusion of animal data. In practice, this bias represents a major rate-limiting step in clinical translation. Even when a research question can be definitively and more human-relevantly answered using validated human-derived in vitro or in silico models, investigators routinely face review comments demanding traditional in vivo alignment. This automatic escalation to animal models driven by reviewer compliance rather than scientific necessity not only wastes animal lives on redundant validation, but as the translational failure of neuroprotective agents like NXY-059 demonstrates [3], can inflate clinical expectations based on models with limited external validity.

To successfully implement the cultural and structural changes Ineichen [1] proposes, the responsibility must shift heavily onto journal editors, reviewers, and funding bodies to actively deconstruct this path dependency: Enforcing Epistemological Equality for NAMs [4]: Journal reviewers must be trained to judge a study by its methodological rigor and alignment with human biology, not by the complexity of its organismal model. If a human-relevant alternative provides a robust mechanistic answer, demanding subsequent animal replication adds little value and should be flagged by editors as an ethical and scientific violation. Operationalizing Regulatory and Funding Guidance: While initiatives like the NIH’s prioritization of human-based research and the FDA/EMA evaluation frameworks for NAM evidence are monumental steps forward, they must be hardwired into local ethics committees and grant review panels. Funding approval should require an explicit, systematic justification of why a whole-organism model is necessary if computational or organoid systems are available. Rewarding Structural Transparency Over “Positive” Stories: As adherence to reporting standards like ARRIVE [5] remains inconsistent, journals must mandate pre-registration and the structured reporting of all design features including blinding and sample size calculations to suppress the systemic risks of p-hacking and selective outcome reporting.

Ineichen’s [1] assertion that the sequence matters fewer unnecessary studies, better-designed studies, and clear alignment with realistic objectives is a standard the translational community must enforce. However, until the gatekeepers of scientific publishing and academic promotion stop treating in vivo data as the mandatory “gold standard” for mechanistic validation, the transition away from redundant animal experimentation will remain stalled. We must align our institutional incentives with biological relevance to honor both science and responsibility.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

There is no financial support for this work.

Data availability

No specific data or materials were generated or analyzed in this letter.

Declarations

Ethics declarations

Not applicable

Conflict of interest

The authors declare no competing interests.

Consent of publication

The authors declare that they have obtained consent from all co - authors for the submission and publication of this letter, and that it is not being simultaneously submitted to other journals.